danyan xu

Dr. danyan xu

second xiangya hospital of central south university

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2023 in Frontiers in Pharmacology
Verified
Journal Article
Open access
YFYu Feng
Yu Feng
DXdanyan xu
danyan xu
Short-chain fatty acids (SCFAs) are metabolites produced by gut bacteria and play a crucial role in various inflammatory diseases. Increasing evidence suggests that SCFAs can improve the occurrence and progression of atherosclerosis. However, the molecular mechanisms through which SCFAs regulate the development of atherosclerosis have not been fully elucidated. This review provides an overview of the research progress on SCFAs regarding their impact on the risk factors and pathogenesis associated with atherosclerosis, with a specific focus on their interactions with the endothelium and immune cells. These interactions encompass the inflammation and oxidative stress of endothelial cells, the migration of monocytes/macrophages, the lipid metabolism of macrophages, the proliferation and migration of smooth muscle cells, and the proliferation and differentiation of Treg cells. Nevertheless, the current body of research is insufficient to comprehensively understand the full spectrum of SCFAs’ mechanisms of action. Therefore, further in-depth investigations are imperative to establish a solid theoretical foundation for the development of clinical therapeutics in this context.

19 October 2020 in Critical Care
Verified
Journal Article
Open access
PDF file
HLHao Lei
Hao Lei
JHJiahui Hu
Jiahui Hu
LLLeiling Liu
Leiling Liu
DXdanyan xu
danyan xu
Background: Out-of-hospital cardiac arrest (OHCA) is a leading cause of sudden cardiac death worldwide. Researchers have found significant pathophysiological differences between females and males and clinically significant sex differences related to medical services. However, conflicting results exist and there is no uniform agreement regarding sex differences in survival and prognosis after OHCA. Therefore, we investigated the relationship between the prognosis of OHCA and sex factors. Methods: We comprehensively searched the PubMed, Embase, and Cochrane databases and obtained a total of 1042 articles, from which 33 studies were selected for inclusion. The pooled odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using a random-effects model. Results: The meta-analysis included 1,268,664 patients. Compared with males, females were older (69.7 years vs. 65.4 years, p < 0.05) and more frequently suffered OHCA without witnesses (58.39% vs 62.70%, p < 0.05). Females were less likely to receive in-hospital interventions than males. There was no significant difference between females and males in the survival from OHCA to hospital admission (OR 0.99, 95% CI 0.89–1.1). However, females had lower chances for survival from hospital admission to discharge (OR 0.59, 95% CI 0.48–0.73), overall survival to hospital discharge (OR 0.73, 95% CI 0.62–0.86), and favorable neurological outcomes (OR 0.62, 95% CI 0.47–0.83) compared with males. Conclusions: Our results indicate that the overall discharge survival rate of females is lower than that of males, and females face a poor prognosis of the nervous system. This is likely related to the pathophysiological characteristics of females, more conservative treatment measures compared with males, and different post-resuscitation care. However, these findings should be interpreted with caution due to the presence of several confounding factors.

14 September 2019 in Lipids in Health and Disease
Verified
Journal Article
Open access
PDF file
CZChao Zhang
Chao Zhang
JCJingyuan Chen
Jingyuan Chen
YLYuhao Liu
Yuhao Liu
DXdanyan xu
danyan xu
Sialic acid (Sia), the acylated derivative of the nine-carbon sugar neuraminic acid, is a terminal component of the oligosaccharide chains of many glycoproteins and glycolipids. In light of its important biological and pathological functions, the relationship between Sia and coronary artery disease (CAD) has been drawing great attentions recently. Large-scale epidemiological surveys have uncovered a positive correlation between plasma total Sia and CAD risk. Further research demonstrated that N-Acetyl-Neuraminic Acid, acting as a signaling molecule, triggered myocardial injury via activation of Rho/ROCK-JNK/ERK signaling pathway both in vitro and in vivo. Moreover, there were some evidences showing that the aberrant sialylation of low-density lipoprotein, low-density lipoprotein receptor and blood cells was involved in the pathological process of atherosclerosis. Significantly, the Sia regulates immune response by binding to sialic acid-binding immunoglobulin-like lectin (Siglecs). The Sia-Siglecs axis is involved in the immune inflammation of atherosclerosis. The generation of Sia and sialylation of glycoconjugate both depend on many enzymes, such as sialidase, sialyltransferase and trans-sialidase. Abnormal activation or level of these enzymes associated with atherosclerosis, and inhibitors of them might be new CAD treatments. In this review, we focus on summarizing current understanding of Sia metabolism and of its relevance to atherosclerosis.

1 January 2021 in Adipocyte
Verified
Journal Article
Open access
QWQiong Wang
Qiong Wang
YWYurong Wang
Yurong Wang
DXdanyan xu
danyan xu
Adipose tissue inflammation in obese patients can cause a series of metabolic diseases. There are a variety of immune cells in adipose tissue, and studies have shown that T cells are associated with adipose tissue inflammation. This review aims to describe the current understanding of the relationship between T cells and adipose tissue inflammation, with a focus on regulation by T cell subtypes. Studies have shown that Th1, Th17 and CD8+ T cells, which are important T cell subsets, can promote the development of adipose tissue inflammation, whereas Treg cells protect against inflammation, suggesting that targeting the mechanism by which T cell subtypes regulate adipose tissue inflammation is a potential therapeutic strategy for treating obesity. T cells play important roles in regulating obesity-associated adipose tissue inflammation, thus providing new research directions for the treatment of obesity. More studies are needed to clarify how T cell subtypes regulate adipose tissue inflammation to identify new treatments for obesity.

27 December 2024 in eClinicalMedicine
Verified
Journal Article
Open access
LLLeiling Liu
Leiling Liu
ZLZhiqi Li
Zhiqi Li
WYWenrui Ye
Wenrui Ye
PPPu Peng
Pu Peng
YWYurong Wang
Yurong Wang
JZJingjing Zhang
Jingjing Zhang
Overweight and obesity pose serious health challenges for individuals and societies. This study aims to facilitate personalised treatment of obesity by summarising recent research on weight-loss pharmacotherapies, with a focus on their effects on weight reduction, cardiometabolic health, psychological outcomes, and adverse events. This systematic review and meta-analysis included searches of Web of Science, PubMed, and Cochrane Central Register of Controlled Trials from inception to June 8, 2024. Randomised controlled trials evaluating weight-loss pharmacotherapies approved by the Food and Drug Administration (FDA) or European Medicines Agency (EMA) for treating overweight or obesity were included. Primary outcomes included changes in body weight, cardiometabolic indicators, psychological outcomes, and adverse events. Summary data was extracted from published reports. Random-effects meta-analyses were used to calculate weighted mean differences (WMDs), risk ratios (RRs), and 95% confidence intervals (CI). The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system was used to assess the certainty of evidence for each pooled analysis. PROSPERO registration: CRD42024547905. A total of 154 randomised controlled trials (n = 112,515 participants) were included. Tirzepatide had the greatest weight-loss effect (WMD −11.69, 95% CI −19.22 to −4.15; P = 0.0024; I2 = 100.0%; moderate certainty), followed by semaglutide (−8.48, −12.68 to −4.27; P < 0.0001; I2 = 100.0%; moderate certainty). Tirzepatide had the strongest antihypertensive effect on both systolic (WMD −5.74, −9.00 to −2.48; P = 0.0006; I2 = 99.8%; moderate certainty) and diastolic blood pressure (WMD −2.91, −4.97 to −0.85; P = 0.0056; I2 = 99.8%; moderate certainty) and best reduced triglycerides (WMD −0.77, −0.85 to −0.69; P < 0.0001; I2 = 3.2%; high certainty), fasting glucose (WMD −3.06, −5.53 to −0.59; P = 0.015; I2 = 100.0%; moderate certainty), insulin (WMD −4.91, −8.15 to −1.68; P = 0.0029; I2 = 97.0%; moderate certainty), and glycated haemoglobin levels (WMD −1.27, −1.82 to −0.73; P < 0.0001; I2 = 100.0%; moderate certainty). Semaglutide (RR 0.83, 0.74–0.92; P < 0.0001; I2 = 0.0%; high certainty) and liraglutide (0.87, 0.79–0.96; P = 0.0059; I2 = 0.0%; high certainty) reduced the risk of major adverse cardiovascular events (MACEs). However, all three medications were associated with adverse gastrointestinal effects. Naltrexone/bupropion increased the risk of elevated blood pressure (RR 1.72, 1.04–2.85; P = 0.036; I2 = 0.0%; high certainty). Topiramate increased depression risk (RR 1.62, 1.14 to 2.30; P = 0.0077; I2 = 0.0%; high certainty), and phentermine/topiramate raised concerns about anxiety (RR 1.91, 1.09 to 3.35; P = 0.025; I2 = 29.5%; high certainty), sleep disorders (RR 1.55, 1.24–1.93; P < 0.0001; I2 = 0.0%; high certainty), and irritability (RR 3.31, 1.69–6.47; P < 0.0001; I2 = 0.0%; high certainty). No medication increased the risk of serious adverse events. For weight reduction, tirzepatide is the top choice, followed by semaglutide. Considering cardiometabolic risk factors, tirzepatide shows the best blood pressure- and glucose-lowering benefits, while semaglutide and liraglutide reduce the risk of MACEs. Naltrexone/bupropion carries a risk of increased blood pressure. Phentermine/topiramate should be used with caution due to its higher risk of psychological side effects. Despite limitations related to study heterogeneity, these findings provide valuable insights for weight management strategies across diverse individuals. 10.13039/501100001809 National Natural Science Foundation of China , Leading Talents Program of Hunan Province, and 10.13039/501100012476 Fundamental Research Funds for the Central Universities of Central South University .

22 December 2020 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
YTYing Tang
Ying Tang
JBJinghui Bao
Jinghui Bao
JHJiahui Hu
Jiahui Hu
LLLeiling Liu
Leiling Liu
DXdanyan xu
danyan xu
Circular RNAs (circRNAs) are a group of covalently closed, endogenous, non‐coding RNAs, which exist widely in human tissues including the heart. Increasing evidence has shown that cardiac circRNAs play crucial regulatory roles in cardiovascular diseases (CVDs). In this review, we aimed to provide a systemic understanding of circRNAs with a special emphasis on the cardiovascular system. We have summarized the current research on the classification, biogenesis and properties of circRNAs as well as their participation in the pathogenesis of CVDs. CircRNAs are conserved, stable and have specific spatiotemporal expression; thus, they have been accepted as a potential diagnostic marker or an incremental prognostic biomarker for CVDs.